Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067093 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,452
- Enrollment target
NCT00067093 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 1,452 participants.
The verdict
NCT00067093, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,452 participants
- Enrollment target
Study Summary
Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep vein thrombosis. The standard treatment includes injections or infusions of an anticoagulant drug (Unfractionated Heparin or low molecular weight heparin) for about a week, followed by vitamin K antagonist (VKA) anticoagulant tablets (warfarin or acenocoumarol) which are taken by mouth. Eligible patients will be assigned to treatment with either SanOrg34006 or the combination of Unfractionated Heparin or low molecular weight heparin plus a VKA (warfarin or acenocoumarol) by random chance. Treatment will be known to both patients and their doctors.
Interventions
- DRUG Vitamin K antagonist (VKA)
- DRUG Unfractionated heparin
- DRUG SanOrg34006
- DRUG LMW heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,452 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00067093
The ClinicalTrials.gov registry entry for NCT00067093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vitamin K antagonist (VKA) is the first listed.
NCT00067093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00067093 about?
NCT00067093 is a clinical study titled "Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)". Patients who have deep vein thrombosis (blood clot in the leg) will be treated in this study. The purpose of the study is to compare the safety and effectiveness of a new injectable anticoagulant (blood thinning) drug administered once each week, SanOrg34006, with the standard way of treating deep v...
What is the current status of trial NCT00067093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,452 participants. The study started on 2003-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00067093?
The interventions under investigation include: Vitamin K antagonist (VKA) (DRUG), Unfractionated heparin (DRUG), SanOrg34006 (DRUG), LMW heparin (DRUG).
Who is sponsoring clinical trial NCT00067093?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.